The nationwide mpox outbreak vaccination programme is due to come to a close at the end of July.
Article continues below
However, the UK Health Security Agency (UKHSA) has announced today that vaccinations will be available beyond this date in London after 11 new cases were diagnosed within the past few weeks.
The majority of these cases were in unvaccinated individuals and 3 were in those who had only received one dose.
The highest risk from mpox is currently in London, primarily in interconnected sexual networks of gay, bisexual, or other men who have sex with men.
This is where the majority of cases have been detected so far this year. Nationally, vaccine remains available for the next 6 weeks.
After the end of July, people who are regularly travelling to London or abroad to have sex and are eligible for the vaccine will be able to book a London-based appointment using the vaccine finder.
Those eligible for the vaccine include gay, bisexual or other men who have sex with men who have multiple sexual partners, participate in group sex or attend sex on premises venues. Staff who work in these premises are also eligible.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "It is vital we respond to recent rises in cases, and that is why we are extending mpox vaccinations in London. If you live in London or regularly travel there or abroad and have sex and are eligible for vaccination, please do consider it.
"The vaccination programme remains open nationwide for everyone eligible until the end of July, and I would urge all those who haven’t yet received their first or second dose to come forward.
"While mpox infection is mild for many, it can cause severe symptoms including unusual rashes and blisters, a fever and headache, so it’s important people remain alert to the risks. Vaccination is key to reducing the severity of symptoms and preventing further transmission."
Case numbers remain low nationwide with just 21 cases of mpox reported in the UK since the beginning of the year.
Everyone at highest risk from mpox is eligible for 2 doses of the vaccine; UKHSA data has shown that one dose of the vaccine offers 78% protection against the virus from 14 days after receiving it, and the second dose aims to provide longer term protection. ■